Rapid eye movement sleep resemblance to waking life), and incorporation of instinctual themes. Sometimes they include elements of the dreamer's recent experience taken directly from episodic memory. By one estimate, 80% of dreams occur during REM. Hobson and McCarley proposed that the PGO waves characteristic of “phasic” REM might supply the visual cortex and forebrain with electrical excitement which amplifies the hallucinatory aspects of dreaming. However, people woken up during sleep do not report significantly more bizarre dreams during phasic REMS, compared to tonic REMS. Another possible relationship between the two phenomena could be that the higher threshold for sensory interruption during REM sleep
Moclobemide on REM sleep; in contrast, depressed people who have been treated with moclobemide, progressively show improved sleep over a 4-week period, with an increase in stage 2 non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep. There have been conflicting findings with regard to moclobemide altering cortisol levels and whether moclobemide increases growth hormone levels. Testosterone levels increase significantly with long-term use of moclobemide in depressed males. Moclobemide also has neuroprotective properties in its demonstrated anti-hypoxia or anti-ischemia effects; there is a possibility that moclobemide may possess similar neuro-rescuing properties, similar to selegiline, however, research is required to